CCR4 and neoplasm: The CC chemokine ligand 22 (CCL22) and the weaker CC chemokine ligand 2 (CCL2) are among the first molecules revealed to attract Tregs to the tumor site by binding to CC chemokine receptor 4 (CCR4) (46, 47).